{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:01:10Z","timestamp":1762354870892,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000770","name":"University of Manchester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["ESR-15-11304"],"award-info":[{"award-number":["ESR-15-11304"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1136\/ijgc-2024-005455","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T13:20:38Z","timestamp":1715260838000},"page":"1034-1040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial"],"prefix":"10.1016","volume":"34","author":[{"given":"Alexander D","family":"Murphy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catharine","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7317-6304","authenticated-orcid":false,"given":"Ann","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alys","family":"Irving","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruby","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Casbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3683-7972","authenticated-orcid":false,"given":"Reem D","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Karanth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsey","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Arnetoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zena","family":"Salih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurjees","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0612-0954","authenticated-orcid":false,"given":"Robert D","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4200-0186","authenticated-orcid":false,"given":"Andrew R","family":"Clamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8515-8944","authenticated-orcid":false,"given":"Gordon C","family":"Jayson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2024-005455_bb0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2024-005455_bb0015","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2024-005455_bb0020","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2024-005455_bb0025","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2024-005455_bb0030","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005455_bb0035","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005455_bb0040","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2024-005455_bb0045","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(20)30637-9","article-title":"Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial","volume":"22","author":"Pignata","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2024-005455_bb0050","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005455_bb0055","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/s41416-021-01605-5","article-title":"The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer","volume":"126","author":"Murphy","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2024-005455_bb0060","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1158\/0008-5472.CAN-04-4409","article-title":"AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer","volume":"65","author":"Wedge","year":"2005","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2024-005455_bb0065","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","article-title":"Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"27","author":"Matulonis","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005455_bb0070","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2024-005455_bb0075","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-19-4121","article-title":"EVOLVE: a multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression","volume":"26","author":"Lheureux","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2024-005455_bb0080","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ygyno.2022.01.015","article-title":"Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer","volume":"164","author":"Colombo","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005455_bb0085","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-21-1733","article-title":"Cediranib in combination with olaparib in patients without a germline Brca1\/2 mutation and with recurrent platinum-resistant ovarian cancer: phase IIb CONCERTO trial","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2024-005455_bb0090","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.21.02011","article-title":"Olaparib with or without cediranib versus platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (NRG-Gy004): a randomized, open-label","volume":"40","author":"Liu","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005455_bb0095","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41416-023-02567-6","article-title":"Results of a randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer","volume":"130","author":"Nicum","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2024-005455_bb0100","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1200\/JCO.2006.07.2066","article-title":"Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors","volume":"25","author":"Drevs","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005455_bb0105","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2019.04.029","article-title":"Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the dreamtherapy trial","volume":"117","author":"Marti","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2024-005455_bb0110","first-page":"45","article-title":"Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II\/III rectal cancer","volume":"11","author":"Spigel","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"10.1136\/ijgc-2024-005455_bb0115","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cncr.27890","volume":"119","author":"Landry","year":"2013","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2024-005455_bb0120","first-page":"A281","article-title":"CEBOC, a single-arm phase II trial to evaluate the safety of Cediranib in the prevention of bowel Perforation in platinum resistant ovarian cancer","volume":"32","author":"Murphy","year":"2023","journal-title":"Int J Gynecol Cancer"},{"year":"2020","key":"10.1136\/ijgc-2024-005455_bb0125"},{"key":"10.1136\/ijgc-2024-005455_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000463","article-title":"Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer","volume":"4","author":"Morgan","year":"2019","journal-title":"ESMO Open"},{"key":"10.1136\/ijgc-2024-005455_bb0135","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2024-005455_bb0140","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2018.03.058","article-title":"Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer","volume":"150","author":"Liu","year":"2018","journal-title":"Gynecologic Oncology"},{"key":"10.1136\/ijgc-2024-005455_bb0145","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/annonc\/mdm508","article-title":"Management of bevacizumab-associated bowel perforation: a case series and review of the literature","volume":"19","author":"Badgwell","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005455_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.04.061","article-title":"Malignant bowel obstruction in advanced ovarian cancer: a retrospective analysis of patients supported with parenteral nutrition","volume":"33","author":"Wight","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005455_bb0155","article-title":"Inoperable malignant bowel obstruction in advanced ovarian cancer: a retrospective analysis of Prognostic radiological features in patients support with parenteral nutrition","volume":"32","author":"Wight","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005455_bb0160","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.19.00194","article-title":"Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives","volume":"37","author":"Pujade-Lauraine","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005455_bb0165","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1200\/JCO.22.02915","article-title":"Ofranergene obadenovec (Ofra-Vec, VB-111) with weekly paclitaxel for platinum-resistant ovarian cancer: randomized controlled phase III trial","volume":"42","author":"Arend","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005455_bb0170","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/IGC.0b013e3182049273","article-title":"Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube","volume":"21","author":"Griffiths","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005455_bb0175","doi-asserted-by":"crossref","first-page":"100417","DOI":"10.1016\/j.esmoop.2022.100417","article-title":"Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers","volume":"7","author":"Zhou","year":"2022","journal-title":"ESMO Open"},{"key":"10.1136\/ijgc-2024-005455_bb0180","doi-asserted-by":"crossref","first-page":"e1066","DOI":"10.1200\/JOP.18.00793","article-title":"Optimizing the care of malignant bowel obstruction in patients with advanced gynecologic cancer","volume":"15","author":"Lee","year":"2019","journal-title":"J Oncol Pract"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24014518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24014518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2024-005455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:57:17Z","timestamp":1762354637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24014518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1048891X24014518"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2024-005455","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2024-005455","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}